Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 1961-1973

  Sullivan, Richard ^a   Paré, Geneviève C ^a   Frederiksen, Lisa J ^a   Semenza, Gregg L ^b   Graham, Charles H ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOXANTRONE; SMALL INTERFERING RNA; STAUROSPORINE;

ALPHA CHAIN; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER RESISTANCE; CARCINOMA CELL; CELL AGING; CELL HYPOXIA; CELL NUCLEUS; CELL POPULATION; CELL STRAIN HCT116; CELL STRUCTURE; CELL SURVIVAL; CLONOGENIC ASSAY; COLON CARCINOMA; CONTROLLED STUDY; CYTOPLASM; DRUG EXPOSURE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; SENESCENCE; CELL SHAPE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; PHENOTYPE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL HYPOXIA; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; PHENOTYPE; RNA, SMALL INTERFERING; STAUROSPORINE; TUMOR STEM CELL ASSAY;

EID: 51049113430     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0198     Document Type: Article

References (35)

1. Frederiksen LJ, Sullivan R, Maxwell LR, et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 2007;13:2199-206.
2. Frederiksen LJ, Siemens DR, Heaton JP, Maxwell LR, Adams MA, Graham CH. Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. J Urol 2003;170:1003-7.
3. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 2001;93:1879-85.
4. Vaupel P, Kelleher DK, Hockel M. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28:29-35.
5. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 2007;26:311-7.
6. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
7. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
8. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 2003;22:3213-20.
9. Erler JT, Cawthorne CJ, Williams KJ, et al. Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004;24:2875-89.
10. Brown LM, Cowen RL, Debray C, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 2006;69:411-8.
11. Hussein D, Estlin EJ, Dive C, Makin GWJ. Chronic hypoxia promotes hypoxia-inducible factor-1α-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 2006;5:2241-50.
12. Song X, Liu X, Chi W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene. Cancer Chemother Pharmacol 2006;58:776-84.
13. Schnitzer SE, Schmid T, Zhou J, Brune B. Hypoxia and HIF-1α protect A549 cells from drug-induced apoptosis. Cell Death Differ 2006;13:1611-3.
14. Chang BD, Xuan YZ, Broude EV, et al. Role of p53 and p21(waf1/cip1) in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999;18:4808-18.
15. Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999;59:3761-7.
16. Chang BD, Swift ME, Shen M, Fang J, Broude EV, Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A 2002;99:389-94.
17. Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 2005;7:816-23.
18. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-83.
19. Elmore LW, Rehder CW, Di X, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J 4 Biol Chem 2002;277:35509-15.
20. Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 1996;56:4006-12.
21. Ruth AC, Roninson IB. Effects of the multidrug transporter P-glycoprotein on cellular responses to ionizing radiation. Cancer Res 2000;60:2576-8.
22. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res 2003;9:2856-65.
23. Dimri GP, Lee XH, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
24. Fang Y, Sullivan R, Graham CH. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res 2007;313:867-77.
25. Sherwood SW, Rush D, Ellsworth JL, Schimke RT. Defining cellular senescence in IMR-90 cells: a flow cytometric analysis. Proc Natl Acad Sci U S A 1988;85:9086-90.
26. Sugrue MM, Shin DY, Lee SW, Aaronson SA. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci U S A 1997;94:9648-53.
27. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001;4:303-13.
28. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-52.
29. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279-82.
30. Seimiya H, Tanji M, Oh-hara T, Tomida A, Naasani I, Tsuruo T. Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochem Biophys Res Commun 1999;260:365-70.
31. Yatabe N, Kyo S, Maida Y, et al. HIF-1-mediated activation of telomerase in cervical cancer cells. Oncogene 2004;23:3708-15.
32. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 2004;24:6076-83.
33. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 2006;25:61-9.
34. Kato H, Inoue T, Asanoma K, Nishimura C, Matsuda T, Wake N. Induction of human endometrial cancer cell senescence through modulation of HIF-1α activity by EGLN1. Int J Cancer 2006;118:1144-53.
35. Welford SM, Bedogni B, Gradin K, Poellinger L, Broome PM, Giaccia AJ. HIF1α delays premature senescence through the activation of MIF. Genes Dev 2006;20:3366-71.